ArticleBMJ open2024
Economic burden of acute kidney injury in children and adults: a protocol for a systematic review and meta-analysis.
Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association between serum lactate trajectories and short-term mortality in pediatric acute kidney injury patients.Jornal de pediatria · 2026Article
- Update on Perioperative Prevention of Cardiac Surgery-Associated Acute Kidney Injury.Journal of clinical medicine · 2026Review
- AKI prediction model in acute aortic dissection surgery: nomogram development and validation.Frontiers in medicine · 2025Article
- Identifying High-Risk Patients for Postoperative Renal Complications Following Femoral Intramedullary Fixation: A NSQIP Study.Orthopedic reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute kidney injury (AKI) is common in hospitalised adults and children and is associated with significantly increased mortality and worse short-term and long-term outcomes. This systematic review and meta-analysis will evaluate the cost associated with AKI. METHODS AND ANALYSIS: This health economic analysis will be performed using systematic search of databases, including MEDLINE, EMBASE, CINAHL, Scopus and Cochrane Library from 2009 to the present (search completed on 27 May 2024). Two reviewers will independently complete study selection, data extraction and bias assessment. Inclusion criteria will be randomised controlled trials (RCTs) and observational studies (cohort or case-control) from all countries of hospitalised adults and children. The exposure will be AKI based on definitions using serum creatinine and/or urine output criteria, relative to patients without AKI. The primary outcome studied will be the cost of index hospitalisation associated with AKI episode. Other secondary outcomes will include the cost of intensive care unit admission during index hospitalisation, direct costs related to inpatient and outpatient care) and indirect (time) costs related to loss of productivity. Pooled random-effect meta-analysis ORs with 95% CIs will be reported. ETHICS AND DISSEMINATION: Ethics approval was not required due to study methodology. The authors have no competing interests to report. The results will be disseminated in peer-reviewed publications according to guidelines by the Cochrane and Centre for Reviews and Dissemination. PROSPERO REGISTRATION NUMBER: CRD42024512658.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.